{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:58:25Z","timestamp":1794376705808,"version":"4.9.0"},"reference-count":59,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"publisher","award":["2023YFC2506100"],"award-info":[{"award-number":["2023YFC2506100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471087"],"award-info":[{"award-number":["82471087"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82220108016"],"award-info":[{"award-number":["82220108016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U25A6002"],"award-info":[{"award-number":["U25A6002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["82471087"],"award-info":[{"award-number":["82471087"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"award":["82220108016"],"award-info":[{"award-number":["82220108016"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"award":["U25A6002"],"award-info":[{"award-number":["U25A6002"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2024A1515030268"],"award-info":[{"award-number":["2024A1515030268"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Funds of the State Key Laboratory of Ophthalmology","award":["20250ZLH08"],"award-info":[{"award-number":["20250ZLH08"]}]},{"award":["20250ZLH08"],"award-info":[{"award-number":["20250ZLH08"]}],"id":[{"id":"https:\/\/ror.org\/003mfbe21","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Program for Supporting and Cultivating Outstanding Scientific and Technological Talents, Zhongshan Ophthalmic Center, Sun Yat-sen University","award":["GCCRC-2026006"],"award-info":[{"award-number":["GCCRC-2026006"]}]},{"name":"Program for Supporting and Cultivating Outstanding Scientific and Technological Talents, Zhongshan Ophthalmic Center, Sun Yat-sen University","award":["GJYXQN-001"],"award-info":[{"award-number":["GJYXQN-001"]}]},{"award":["GCCRC-2026006"],"award-info":[{"award-number":["GCCRC-2026006"]}],"id":[{"id":"https:\/\/ror.org\/02z2yec16","id-type":"ROR","asserted-by":"publisher"}]},{"award":["GJYXQN-001"],"award-info":[{"award-number":["GJYXQN-001"]}],"id":[{"id":"https:\/\/ror.org\/02z2yec16","id-type":"ROR","asserted-by":"publisher"}]},{"name":"GBRCE for Major Blinding Eye Diseases Prevention and Treatment"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Wet age-related macular degeneration (wAMD) is characterized by choroidal neovascularization (CNV) and remains a major cause of severe vision loss in older adults. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the current standard of care for wAMD. However, repeated injections are associated with poor adherence, procedure-related complications, and a substantial cumulative treatment burden. Topical nanocarrier-based systems have therefore attracted increasing attention as needle-free approaches for improving posterior segment drug exposure. Complementing broader reviews of ocular nanomedicine, this review specifically examines topical nanocarrier-mediated posterior segment delivery for wAMD, with a focus on three representative platforms: liposomes, polymeric nanoparticles, and polymeric micelles. These systems are engineered through the optimization of particle size, surface properties, drug-loading strategies, and functional modifications to improve payload stability, ocular surface residence, tissue penetration, and lesion-relevant delivery. By integrating formulation design, ocular barrier transport, ocular posterior segment bioavailability, and translational feasibility in the context of wAMD, this review provides a disease-focused and application-oriented perspective that complements existing broader reviews of ocular nanocarriers and ophthalmic nanomedicine. We summarize current evidence from preclinical and translational studies and discuss major barriers limiting clinical application, including insufficient posterior segment drug exposure, dose\u2013safety trade-offs, pharmacokinetic instability, limited targeting efficiency, and challenges in delivering macromolecular biologics, such as anti-VEGF antibodies and fusion proteins. At present, topical nanocarrier-based strategies remain investigational, but they hold potential for development as therapeutic approaches for wAMD. Key priorities for future development include quantitative posterior segment pharmacokinetic\/pharmacodynamic evaluation, long-term safety assessment, payload-specific carrier design, scalable manufacturing, and clinically relevant efficacy endpoints. This review provides a focused framework for the rational design and translational assessment of nanocarrier-based topical strategies for wAMD management.<\/jats:p>","DOI":"10.3390\/pharmaceutics18070861","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:08:34Z","timestamp":1784189314000},"page":"861","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nanocarrier-Mediated Non-Invasive Drug Delivery for Wet Age-Related Macular Degeneration: Advances and Translational Challenges"],"prefix":"10.3390","volume":"18","author":[{"given":"Shasha","family":"Wang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfei","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Zeng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonghui","family":"Tang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuri","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weisi","family":"Lu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-Related Macular Degeneration: A Review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"ref_2","first-page":"e39624","article-title":"Age-Related Macular Degeneration: An Exponentially Emerging Imminent Threat of Visual Impairment and Irreversible Blindness","volume":"15","author":"Chaudhuri","year":"2023","journal-title":"Cureus"},{"key":"ref_3","first-page":"376","article-title":"Emerging therapies for the treatment of wet age-related macular degeneration\u2013VEGF Trap-Eye","volume":"113","author":"Rejdak","year":"2011","journal-title":"Klin. Ocz."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMcp2102061","article-title":"Age-Related Macular Degeneration","volume":"385","author":"Apte","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.addr.2005.09.003","article-title":"Wet age-related macular degeneration","volume":"57","author":"Kulkarni","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Korva-Gurung, I., Kubin, A.M., Ohtonen, P., and Hautala, N. (2023). Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study. Pharmaceuticals, 16.","DOI":"10.20944\/preprints202306.0061.v1"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/14712598.2024.2374869","article-title":"Long-acting delivery and therapies for neovascular age-related macular degeneration","volume":"24","author":"Rowe","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s40123-024-00973-4","article-title":"Vascular Endothelial Growth Factor C and D Signaling Pathways as Potential Targets for the Treatment of Neovascular Age-Related Macular Degeneration: A Narrative Review","volume":"13","author":"Leitch","year":"2024","journal-title":"Ophthalmol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/ICU.0000000000000850","article-title":"Complications of intravitreal injections: 2022","volume":"33","author":"Patel","year":"2022","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Huang, X., Zhang, L., Fu, Y., Zhang, M., Yang, Q., and Peng, J. (2023). Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy. Front. Bioeng. Biotechnol., 11.","DOI":"10.3389\/fbioe.2023.1199922"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"126009","DOI":"10.1016\/j.ijpharm.2025.126009","article-title":"Revolutionizing age-related macular degeneration treatment: Advances and future directions in non-invasive retinal drug delivery systems","volume":"683","author":"Sahu","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"114864","DOI":"10.1016\/j.addr.2023.114864","article-title":"Ocular therapies with biomacromolecules: From local injection to eyedrop and emerging noninvasive delivery strategies","volume":"197","author":"Fan","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jconrel.2023.07.055","article-title":"Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery","volume":"361","author":"Qi","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"114770","DOI":"10.1016\/j.addr.2023.114770","article-title":"Polymer- and lipid-based nanocarriers for ocular drug delivery: Current status and future perspectives","volume":"196","author":"Han","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12951-023-01992-2","article-title":"Nanotechnology-based ocular drug delivery systems: Recent advances and future prospects","volume":"21","author":"Li","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"114965","DOI":"10.1016\/j.addr.2023.114965","article-title":"Recent advances and prospects for lipid-based nanoparticles as drug carriers in the treatment of human retinal diseases","volume":"199","author":"Zeng","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e03212","DOI":"10.1002\/advs.202503212","article-title":"Drug Delivery Technologies for the Treatment of Age-Related Macular Degeneration","volume":"12","author":"Cutrufello","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"L\u00f6scher, M., Seiz, C., Hurst, J., and Schnichels, S. (2022). Topical Drug Delivery to the Posterior Segment of the Eye. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010134"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"114398","DOI":"10.1016\/j.jconrel.2025.114398","article-title":"Intraocular fate of surface charge-dependent nanomicelles via topical administration: Posterior delivery and transport pathway","volume":"388","author":"Wei","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.jconrel.2024.10.052","article-title":"A single molecule carrier for ocular posterior segment diseases","volume":"376","author":"Zhang","year":"2024","journal-title":"J. Control. Release"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ajo.2022.02.019","article-title":"A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration","volume":"239","author":"Poor","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/bcp.13794","article-title":"The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: An open-label phase II trial","volume":"85","author":"Joussen","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"27835","DOI":"10.1039\/D0RA04971A","article-title":"Nanocarriers for ocular drug delivery: Current status and translational opportunity","volume":"10","author":"Gorantla","year":"2020","journal-title":"RSC Adv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"113851","DOI":"10.1016\/j.addr.2021.113851","article-title":"Liposome composition in drug delivery design, synthesis, characterization, and clinical application","volume":"176","author":"Large","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2147\/IJN.S446425","article-title":"Topical Ophthalmic Liposomes Dual-Modified with Penetratin and Hyaluronic Acid for the Noninvasive Treatment of Neovascular Age-Related Macular Degeneration","volume":"19","author":"Sun","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_32","first-page":"198","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-tap report 2","volume":"119","author":"Bressler","year":"2001","journal-title":"Arch. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.actbio.2023.05.021","article-title":"Targeted long-term noninvasive treatment of choroidal neovascularization by biodegradable nanoparticles","volume":"166","author":"Yao","year":"2023","journal-title":"Acta Biomater."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Eltaib, L. (2025). Polymeric Nanoparticles in Targeted Drug Delivery: Unveiling the Impact of Polymer Characterization and Fabrication. Polymers, 17.","DOI":"10.3390\/polym17070833"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jconrel.2024.12.068","article-title":"Adhesive polyelectrolyte coating on PLGA particles prolongs drug retention to vessel lesion","volume":"378","author":"Yin","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2147\/IJN.S126865","article-title":"Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles","volume":"12","author":"Chu","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_37","first-page":"394","article-title":"Feasibility of drug delivery to the eye\u2019s posterior segment by topical instillation of PLGA nanoparticles","volume":"12","author":"Tahara","year":"2017","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"107016","DOI":"10.1016\/j.ejps.2025.107016","article-title":"Optimized PLGA encapsulated SA-2 nanosuspension exhibits sustained intraocular pressure reduction in the mouse microbead occlusion model of ocular hypertension","volume":"206","author":"Amankwa","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2017.01.012","article-title":"Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies","volume":"248","author":"Mandal","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1039\/D1NA00596K","article-title":"Flexible polymeric nanosized micelles for ophthalmic drug delivery: Research progress in the last three years","volume":"3","author":"Li","year":"2021","journal-title":"Nanoscale Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jconrel.2024.11.050","article-title":"Active trans-corneal drug delivery with ocular adhesive micelles for efficient glaucoma therapy","volume":"377","author":"Wei","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e2108360","DOI":"10.1002\/adma.202108360","article-title":"Antiangiogenic Nanomicelles for the Topical Delivery of Aflibercept to Treat Retinal Neovascular Disease","volume":"34","author":"Zhao","year":"2022","journal-title":"Adv. Mater."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e2314126","DOI":"10.1002\/adma.202314126","article-title":"Enhanced Ocular Delivery of Beva via Ultra-Small Polymeric Micelles for Noninvasive Anti-VEGF Therapy","volume":"36","author":"Yang","year":"2024","journal-title":"Adv. Mater."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"115356","DOI":"10.1016\/j.carbpol.2019.115356","article-title":"Functional chitosan oligosaccharide nanomicelles for topical ocular drug delivery of dexamethasone","volume":"227","author":"Xu","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"126248","DOI":"10.1016\/j.ijpharm.2025.126248","article-title":"Ocular implants and inserts: Revolutionizing drug delivery in ophthalmology","volume":"685","author":"Chhoker","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"115321","DOI":"10.1016\/j.addr.2024.115321","article-title":"Recent advances and strategies for nanocarrier-mediated topical therapy and theranostic for posterior eye disease","volume":"210","author":"Faria","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2014.05.031","article-title":"Nanotherapy for posterior eye diseases","volume":"193","author":"Kaur","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"124192","DOI":"10.1016\/j.ijpharm.2024.124192","article-title":"Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics","volume":"658","author":"Datta","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"144151","DOI":"10.1016\/j.ijbiomac.2025.144151","article-title":"Topical delivery of anti-VEGF macromolecules for retinopathy: A review","volume":"312","author":"Regu","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"101229","DOI":"10.1016\/j.mtbio.2024.101229","article-title":"Nanomedicine in glaucoma treatment; Current challenges and future perspectives","volume":"28","author":"Iqbal","year":"2024","journal-title":"Mater. Today Bio"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2476140","DOI":"10.1080\/10717544.2025.2476140","article-title":"External stimuli-responsive drug delivery to the posterior segment of the eye","volume":"32","author":"Xu","year":"2025","journal-title":"Drug Deliv."},{"key":"ref_52","first-page":"100477","article-title":"Hydrogel-encapsulated antioxidant nanotherapeutics against age-related macular degeneration (AMD) oxidative damage","volume":"11","author":"Xu","year":"2026","journal-title":"Int. J. Pharm. X"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17425247.2019.1597848","article-title":"Topical application of polymeric nanomicelles in ophthalmology: A review on research efforts for the noninvasive delivery of ocular therapeutics","volume":"16","author":"Grimaudo","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e08104","DOI":"10.1002\/adma.202508104","article-title":"Trojan Horse-Inspired Biomimetic Lipoprotein Nanocarrier for Noninvasive Anti-VEGF Therapy of Ocular Fundus Neovascularization","volume":"37","author":"Chen","year":"2025","journal-title":"Adv. Mater."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"125379","DOI":"10.1016\/j.ijpharm.2025.125379","article-title":"A novel bevacizumab delivery system using solid lipid nanoparticles for potential wet age-related macular degeneration treatment: An in vivo study","volume":"673","author":"Accomasso","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"121725","DOI":"10.1016\/j.ijpharm.2022.121725","article-title":"Liposomal sunitinib for ocular drug delivery: A potential treatment for choroidal neovascularization","volume":"620","author":"Tavakoli","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.apsb.2023.09.001","article-title":"pH-Responsive polymer boosts cytosolic siRNA release for retinal neovascularization therapy","volume":"14","author":"Guo","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"57710","DOI":"10.1021\/acsami.0c17296","article-title":"Ophthalmic Drops with Nanoparticles Derived from a Natural Product for Treating Age-Related Macular Degeneration","volume":"12","author":"Xin","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Mahaling, B., Baruah, N., and Dinabandhu, A. (2024). Nanomedicine in Ophthalmology: From Bench to Bedside. J. Clin. Med., 13.","DOI":"10.3390\/jcm13247651"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/7\/861\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:33:12Z","timestamp":1784262792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/7\/861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":59,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["pharmaceutics18070861"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18070861","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}